Roche receives conditional EU approval for cancer drug

ZURICH, July 15 Mon Jul 15, 2013 1:14am EDT

Related Topics

ZURICH, July 15 (Reuters) - Roche said on Monday it had received conditional approval from the European Commission for Erivedge, a drug used to treat adults with basal cell carcinoma, a disfiguring form of skin cancer.

The approval makes Erivedge the first licensed medicine for patients in the European Union with this potentially life-threatening form of skin cancer, Roche said.

(Reporting by Alice Baghdjian)